

Comparison of the Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Two Groups of Patients with Benign and Malignant Salivary Gland Tumors

Mohammad Hossein Shafieyoun¹, Nezamoddin Berjis², *Afrooz Eshaghian²

Abstract

Introduction:

The ratio of neutrophils to peripheral lymphocytes is an inflammatory marker, and, based on previous studies, this ratio is associated with poor survival in several cancers. This study was conducted to compare the neutrophils-to-lymphocytes ratio (NLR) and platelets-to-lymphocytes ratio (PLR) in two groups of patients with benign and malignant salivary gland tumors.

Materials and Methods:

This study was cross-sectional, comparing two groups of patients with benign and malignant salivary gland masses. During the last 6 years (from 2018 to 2024), 380 Patients with a definite diagnosis of salivary gland tumors were included in the study, and NLR and PLR data were obtained from pre-operation laboratory exams.

Results:

NLR and PLR were significantly higher on average than in benign masses ($P < 0.05$). The best cut point was 2.24 for NLR (sensitivity: 78%, specificity: 80%) and 104.35 for PLR (sensitivity: 68%, specificity: 60%).

Conclusion:

NLR and PLR are easy, practical methods that provide valuable information for diagnosing, assessing severity, and predicting prognosis of various diseases, such as salivary gland masses.

Keywords: Neutrophil to lymphocyte ratio, Platelet to lymphocyte ratio, Benign masses, Malignant masses, Salivary glands.

Received date: 18 Jul 2025

Accepted date: 09 Nov 2025


**Please cite this article; Shafieyoun MH, Berjis N, Eshaghian A. Comparison of the Neutrophil-To-Lymphocyte and Platelet-to-Lymphocyte Ratios in Two Groups of Patients with Benign and Malignant Salivary Gland Tumors. Iran J Otorhinolaryngol. 2026;38(1):29-35. Doi: 10.22038/ijorl.2025.89668.4001*

¹Isfahan University of Medical Sciences, faculty of Medicine, Isfahan Iran.

²Department of Otorhinolaryngology, Head and Neck Surgery, Kashani Hospital, School of Medicine, Isfahan University of Medical Sciences, Isfahan Iran.

*Corresponding author:

Otorhinolaryngologist, Head and neck surgery Fellowship, Department of Otolaryngology, School of Medicine, Isfahan University of Medical Sciences.

 Copyright©2026 Mashhad University of Medical Sciences. This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 International License <https://creativecommons.org/licenses/by-nc/4.0/deed.en>

Introduction

Salivary gland tumors (SGT) are complex and heterogeneous histologies that occur in the major glands (parotid, submandibular, and sublingual) and minor salivary glands (1). 80% of these tumors are benign but can recur or transform into malignant lesions. In 2005, the World Health Organization identified 24 malignant SGTs, the most prevalent of which were mucoepidermoid carcinoma, acinic cell carcinoma, and adenoid cystic carcinoma (2).

In 2017, it identified 11 benign epithelial SGTs, the most common of which were pleomorphic adenoma, Warthin, tumor and myoepithelioma (3). Salivary gland malignancies account for 0.5–1.2% of all cancers and 5% of head and neck cancers (4). It affects women more often than men (1.5 to 1 ratio) and is more likely to be malignant in children (5). The risk of malignancy is also 15 to 32% for parotid masses, 41 to 50% for submandibular tumors, 70 to 90% for minor salivary glands, and almost 100% for sublingual masses (6). In minor salivary glands, 50% of tumors are malignant (the most often located in the palate) (7). The incidence rate of SGTs is 1.1 to 1.3 per 100,000 in the United States, compared with 1.31 per 100,000 in Europe and 1.04 per 100,000 in Japan (8). In a recent systematic review, for the Iranian population, the weighted mean prevalence of benign tumors was 66% and malignant tumors was 34% (9). The etiology of SGTs is poorly understood. Similar to other types of head and neck cancers, SGTs are associated with smoking and alcohol consumption (10). In addition, high consumption of processed meat, diets low in vegetables and high animal fat, obesity, and occupational radiation exposure are possible risk factors of salivary tumors. Epstein-Barr virus, immunodeficiency, and HIV infection have also been associated with an increased risk (11).

Some studies have suggested that neutrophils and platelets provide angiogenic, epithelial, and stromal growth factors that promote tumor progression. Several studies have also shown that C-reactive protein (CRP), albumin levels, neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) are associated with cancer stage (12). Interactions between the microenvironment and tumor cells play an important role in cancer progression.

The microenvironment includes metabolic, inflammatory, and immune responses to stimuli from surrounding tissues (13). Recent basic studies have shown that tumor metastasis, microvascular remodeling, and tumor cell proliferation capabilities are influenced by the systemic inflammatory response (14,15). The increase of peripheral NLR (as an inflammatory marker) has been significantly associated with poor survival in several cancers, such as head and neck malignancies (16-18).

Neutrophils are a subgroup of inflammatory cells that produce several factors, such as vascular endothelial growth factor, chemokines, and proteases, to facilitate angiogenesis; they can create a favorable tumor microenvironment that promotes cancer evolution (19). Neutrophils that infiltrate cancerous lesions can disrupt the immunity. In contrast, the number of lymphocytes existing in the tumor microenvironment can disturb the function of natural killer cells. In addition, increasing the number of lymphocytes reduces the levels of cytokines that can induce apoptosis in tumoral cells. Therefore, an increase in the neutrophil-to-lymphocyte ratio shows a poor prognosis for malignant SGTs (20).

However, some of these associations remain unknown. The present study aimed to compare the NLR and PLR in two groups of patients with benign and malignant salivary gland masses over 6 years in Isfahan.

Materials and Methods

The present study was a cross-sectional study comparing two groups of patients with benign and malignant SGTs, conducted in 2024. These patients had undergone surgery with a definitive diagnosis of the salivary gland or glands in two hospitals in Isfahan, Al-Zahra and Kashani, during the past 6 years (from 2018 to 2024). The inclusion criteria were patients aged 18 to 80 years with a pathology report of one or more salivary glands, and a complete blood count test was available in the medical file before the operation.

Patients who had other benign or malignant masses, were on dialysis, pregnant or breastfeeding, or those with inflammatory diseases, such as rheumatic arthritis, autoimmune, and infectious diseases, were not included in the study. After receiving the necessary and ethical permits (from the Faculty

of Medicine, Isfahan University of Medical Sciences, No. IR.MUI.MED.REC.1403.136), the researcher reviewed the records of two hospitals in Isfahan, Al-Zahra and Kashani, and identified patients undergoing surgery with a definitive diagnosis of a salivary gland or glands during the past 6 years. After that, he reviewed the complete medical records and collected the required information using the prepared checklist.

The checklist included the patient's demographic and clinical data, such as age, gender, pathology type, WBC, Neutrophil, Lymphocyte, and Platelet count on his record before surgery. Finally, 380 patients entered the study, and were divided into two groups: benign (322 patients) and malignant (58 patients).

The collected data were analyzed using SPSS version 27 at a significance level of 0.05 with an independent T-test, Mann-whitney, and Chi-square tests, and ROC curve analysis. Sensitivity, specificity, and accuracy of the two main variables for predicting benign and malignant masses were measured using the Area Under the CURE (AUC) plot. Univariate

and multivariate regression were also used to estimate the odds ratios.

Results

All patients with a salivary gland tumor between 2018 and 2024 who had a documented CBC (complete blood count) and pathologic report at our tertiary hospital (Alzahra, Kashani) were included in the study. They excluded those without preoperative laboratory data or a documented pathologic report. Lab data were extracted from a standardized, frequently calibrated cell counter in our hospitals. Three hundred eighty patients entered the study; their demographic and medical characteristics are summarized in Table 1. 322 (84.7%) had benign masses, and 58 (15.3%) had malignant tumors. There was a significant difference in age between the two groups ($P<0.05$). In fact, the mean age of patients with malignant tumors was significantly higher than that of the other group.

In both groups, there were more men than women, but no significant difference was observed ($P>0.05$).

Table 1. Demographic and clinical characteristics of the patients studied, divided into benign and malignant tumors

Variables	Benign tumor	Malignant tumor	Total	p-value
Age (mean \pm SD)	51.43 \pm 16.22	67.43 \pm 17.61	55.19 \pm 17.61	<0.001
Sex distribution %				
Male	186 (57.8%)	38(65.5%)	224(58.9%)	0.269
Female	136(42.2%)	20 (34.5%)	156 (41.1%)	
NLR (mean \pm SD)	1.9 \pm 1.08	4.3 \pm 3.94	2.25 \pm 1.99	<0.001
PLR (mean \pm SD)	106.06 \pm 68.92	158.99 \pm 107.46	113.94 \pm 77.96	<0.001
Plt (mean \pm SD)	232618.03 \pm 71230.39	202090.90 \pm 73559.65	228420.55 \pm 72171.16	0.024
WBC (mean \pm SD)	8233.54 \pm 12384.26	7500 \pm 2579.36	8130.97 \pm 11524.05	0.0735

SD: standard deviation, NLR: neutrophil to lymphocyte ratio, PLR: platelet to lymphocyte ratio, PLt: platelet

NLR and PLR were significantly different between the two groups ($P<0.05$). In both ratios, malignant masses had a significantly higher mean than benign masses. Platelets also showed a significant difference between the two groups ($P<0.05$). Thus, malignant tumors had a significantly higher mean level than benign masses. In Table 2, NLR and PLR are shown by


age and gender. In benign masses, NLR was not significantly different between the two age groups (less than and more than 52 years) ($P>0.05$) (52 years is the mean age of benign tumors). In malignant masses, the NLR did not differ significantly between the two age groups (less than and more than 67 years) ($P>0.05$) (67 years is the mean age of malignant tumors).

Table 2. Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio by Age and Gender

Variables		NLR	PLR
Benign Mass	Male	1.94 ± 1.29	107.87 ± 22.87
	Female	1.85 ± 0.73	103.8±32.29
	P value	0.556	0.675
Malignant Mass	Male	5.02±4.47	165.65 ± 119.75
	Female	2.58 ± 0.85	142.65 ± 70.092
	P value	0.083	0.557
Benign Mass	<= 52 years	1.8± 0.85	117.47 ± 109.18
	More than 52 years	1.72 ± 0.66	94.48 ± 32.2
	P value	0.579	0.107
Malignant Mass	<= 67 years	4.09 ± 4.87	172.57 ± 100.9
	More than 67 years	4.48 ± 3.2	149.11 ± 113.28
	P value	0.772	0.514

Also, in this study, using the obtained data and statistical analyses, such as ROC (Receiver Operating Characteristic), thresholds were determined for each of the NLR and PLR

variables to diagnose benign and malignant masses, which are commonly used in medical diagnostics to evaluate the performance of diagnostic tests.

**Fig 1.** sensitivity and specificity of PLR (Platelet to neutrophil ratio and NLR (neutrophil to lymphocyte ratio)

The NLR threshold value is 2.24, Area under the curve (AUC) for NLR is 0.841 (CI95%: 0.775-0.907), which corresponds to the performance criteria of sensitivity: 78% and specificity: 80%, which means that using the NLR value more than 2.24, the test can correctly identify malignancy with 78% of positive cases (sensitivity) and 80% of negative cases (specificity).

The PLR threshold value is 104.35, AUC for PLR is 0.720 (95%CI: 0.626-0.813), with the following performance criteria: sensitivity: 68% and specificity: 60%, indicates that using a PLR value of more than 104.35 as the threshold, the test can correctly identify 68% of positive cases (sensitivity) and 60% of negative

cases (specificity) of malignant tumors. (Figure1).

These results can be used to evaluate the diagnostic accuracy of NLR and PLR in detecting malignancy. The NLR test appears to perform better overall, with higher AUC, sensitivity, and specificity than the PLR test.

Based on significant univariate logistic regression results for NLR and PLR variables, they were included in a multivariate logistic regression model to predict benign and malignant masses. After performing multivariate logistic regression, only a significant increase in NLR was associated with malignant masses, with a 5-fold odds ratio (Table 3).

Table 3. Unavailable and Multivariate logistic regression analysis between variables

Factors	Unavailable Logistic Regression Analysis		Multivariate Logistic Regression Analysis	
	OR (95% CI)	P value	OR (95% CI)	P value
NLR	1.405 (1.152-1.713)	0.001	5.339 (0.983-29.008)	0.042
PLR	0.982 (0.977-0.987)	0.0001	1.070 (1.011-1.132)	0.020

Discussion

Recent investigations into the immune system have provided valuable insight into the potential impact of the immune response on tumor progression (21,22). Consequently, the significance of immunological biomarkers in cancer treatment and prognostic assessments has been highlighted. The role of the tumor microenvironment in tumor development has also been well recognized. One critical component is the inflammatory microenvironment, in which cells such as neutrophils and lymphocytes play a significant role in tumor progression (23).

Several studies have focused on the importance of the neutrophil-to-lymphocyte ratio as a predictive biomarker for cancer. Kuzucu in Turkey divided and compared patients into two groups based on histopathological findings: patients with malignant or benign parotid tumors (n=145) and a control group (n=83) consisting of healthy individuals. The mean NLR in the malignant, benign, and healthy control groups was 2.51, 2.01, and 1.79, respectively, which were statistically significant differences. The PLR value of the malignant group was also significantly higher than the other two groups (benign, control) (23). Some studies failed to demonstrate PLR's prognostic value in SGTs (24). In the present study, the mean NLR and PLR were much higher in the malignant mass group, and the optimal PLR cut point was 104.25. In Magdum's study of 50 patients, an NLR of 4 or greater was considered a good marker for the presence of oral cancer (Poor prognosis with higher NLR) (25). Cheng also studied 45 patients with primary parotid cancer in China. The mean NLR was 2.48 with a range of 1.5 to 6.1 and was significantly associated with tumor stage, disease stage, and disease grade. They reported in previous studies that the best cutoff value ranged from 1.98 to 5 for head and neck, breast, gynecologic, colorectal, and oral cavity cancers; however, the standard cutoff point remains unknown, and their best

cutoff was 2.48 (26). Szilasi reviewed the clinical data of 156 head and neck squamous cell carcinoma patients for survival in Poland. The results indicated that a higher NLR could be associated with an increased risk of overall survival. Their optimal threshold was 107 for PLR and 3.9 for NLR (27). Lee studied 20 patients with salivary gland cancers treated with pembrolizumab in the United States. The results showed that a high pre-treatment NLR was independently associated with 6-month survival (28). The results of Bora's study in Turkey also showed that the NLR can be used as a biomarker for submandibular gland masses and has prognostic significance in malignant masses (29). In the present study with 380 patients, the NLR was also significantly higher in malignant masses, and the optimal cut point for salivary gland malignancies was 2.24.

Damar also reported that the mean percentage of neutrophils in patients with malignant oral masses was significantly higher than in those with benign oral masses, consistent with the results of the present study (19).

Committeri concluded, after studying 117 patients with SGTs in Italy, that inflammatory biomarkers and radiomic features can provide surgeons with faster information than differential diagnosis before surgery. Their analysis revealed the best cutoff points for separating a benign mass from a malignant one (PLR: 133.30; NLR: 3.62), with an accuracy of 0.88 for NLR (3).

Finally, it should be noted that the NLR and PLR are readily available, cost-effective, and reproducible inflammatory indicators for distinguishing patients with different SGTs from healthy individuals. PLR showed lower accuracy but may still be helpful when combined with NLR or the systemic immune-inflammation index (SII). NLR and PLR are not shown to be impacted by age and gender so that they can be used as promising biomarkers in the absence of prior biopsy. NLR can help limit biopsy decisions and early suspicion of malignancy, and it can help with prognosis.

The limitations of this study include the lack of patient follow-up, a single-region design, a retrospective design, and the absence of a healthy control group. Only 58 malignant cases versus 322 benign; this may affect predictive model robustness, but the prevalence of malignancy in salivary gland tumors is less than the benign number, and imbalance in group sizes is another one of our limitations.

It would also be better to compare these two indices in individuals with malignant and benign masses with healthy individuals, through prospective, multicenter validation and correlation with survival outcomes.

Conclusion

The neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are easy, practical methods that provide valuable information for diagnosing, assessing severity, and predicting prognosis in various diseases, including salivary gland masses. These results can be used to evaluate the diagnostic accuracy of NLR and PLR in detecting malignancy. The NLR test appears to perform a better overall, with higher sensitivity and specificity than the PLR test.

References

1. Skálová A, Hycza MD, Leivo I. Update from the 5th edition of the World Health Organization classification of head and neck tumors: salivary glands. *Head and Neck Pathology*. 2022;16(1):40-53.
2. Barnes L, Eveson JW, Sidransky D, Reichart P. *Pathology and genetics of head and neck tumours*: IARC; 2005.
3. Committeri U, Barone S, Salzano G, Arena A, Borriello G, Giovacchini F, et al. Support Tools in the Differential Diagnosis of Salivary Gland Tumors through Inflammatory Biomarkers and Radiomics Metrics: A Preliminary Study. *Cancers*. 2023; 15(6): 1876.
4. Ettl T, Schwarz-Furlan S, Gosau M, Reichert TE. Salivary gland carcinomas. *Oral and maxillofacial surgery*. 2012;16(3):267-83.
5. Tunç O, Gönüldas B, Kanlıkama M. Systemic Inflammatory Markers as a Prognostic Factor in Parotid Gland Tumors. *Cyprus Journal of Medical Sciences*. 2021;6(2):171-6.
6. Pusztaszeri MP, Faquin WC, editors. *Update in salivary gland cytopathology: recent molecular advances and diagnostic applications*. *Seminars in Diagnostic Pathology*; 2015: Elsevier.
7. Schmidt RL, Hall BJ, Wilson AR, Layfield LJ. A systematic review and meta-analysis of the diagnostic accuracy of fine-needle aspiration cytology for parotid gland lesions. *American journal of clinical pathology*. 2011;136(1):45-59.
8. Lee JIL, Tan HM, Chua DYS, Chung JGK, Nga ME. The Milan system for reporting salivary gland cytology: a retrospective analysis of 1384 cases in a tertiary Southeast Asian institution. *Cancer Cytopathology*. 2020;128(5):348-58.
9. Assar S, Assar S, Mardanifard HA, Jaafari-Ashkavandi Z. Salivary Gland Tumors in Iran: A Systematic Review of 2870 Cases Based on the New WHO Classification. *Iran J Pathol*. 2023;18(1):1-11. doi: 10.30699/IJP.2023.559121.2942. Epub 2023 Mar 23. PMID: 37383154; PMCID: PMC10293605.
10. Colella G, Cannavale R, Flaminio F, Foschini MP. Fine-needle aspiration cytology of salivary gland lesions: a systematic review. *Journal of Oral and Maxillofacial Surgery*. 2010; 68(9): 2146-53.
11. Salgarelli AC, Cappare P, Bellini P, Collini M. Usefulness of fine-needle aspiration in parotid diagnostics. *Oral and maxillofacial surgery*. 2009;13(4):185-90.
12. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. *nature*. 2008; 454 (7203):436-44.
13. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. *Science*. 2011; 331(6024):1565-70.
14. Abbate V, Orabona GDA, Barone S, Troise S, Bonavolontà P, Pacella D, et al. Relevance of Inflammatory Biomarkers in Salivary Gland Cancers Management. *Eurasian J Med Oncol*. 2021; 5:311-7.
15. Whiteside T. The tumor microenvironment and its role in promoting tumor growth. *Oncogene*. 2008; 27(45):5904-12.
16. De Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. *Nature reviews cancer*. 2006; 6(1): 24-37.
17. Lin S-W, Hensley SE, Tatsis N, Lasaro MO, Ertl HC. Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice. *The Journal of clinical investigation*. 2007; 117(12): 3958-70.
18. Kasprzak A. The role of tumor microenvironment cells in colorectal cancer (CRC) cachexia. *International journal of molecular sciences*. 2021; 22(4):1565.
19. Damar M, Dinç AE, Erdem D, Aydil U, Kizil Y, Eravcı FC, et al. Pretreatment neutrophil-lymphocyte ratio in salivary gland tumors is associated with malignancy. *Otolaryngology-Head and Neck Surgery*. 2016; 155(6):988-96.
20. Hu B, Yang X-R, Xu Y, Sun Y-F, Sun C, Guo W, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection

for hepatocellular carcinoma. *Clinical Cancer Research*. 2014;20(23):6212-22.

21. Mascarella MA, Mannard E, Silva SD, Zeitouni A. Neutrophil-to-lymphocyte ratio in head and neck cancer prognosis: a systematic review and meta-analysis. *Head & neck*. 2018; 40(5):1091-100.

22. Gao Y, Guo W, Cai S, Zhang F, Shao F, Zhang G, et al. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected esophageal squamous cell carcinoma. *Journal of Cancer*. 2019;10(14):3188.

23. Kuzucu İ, Güler İ, Kum RO, Baklacı D, Özcan M. Increased neutrophil lymphocyte ratio and platelet lymphocyte ratio in malignant parotid tumors. *Brazilian journal of otorhinolaryngology*. 2020; 86:105-10.

24. 29. Cristofaro MG, Ferragina F, Staglianò S, Arrotta A, D'Amico M, Barca I. Prognostic Value of Systemic Inflammatory Markers in Malignant Tumors of Minor Salivary Glands: A Retrospective Analysis of a Single Center. *Cancers (Basel)*. 2025 Apr 21;17(8):1373. doi: 10.3390/cancers17081373. PMID: 40282549; PMCID: PMC12026184.

25. Magdum DB, Kulkarni NA, Kavle PG, Paraye S, Pohankar PS, Giram AV. Salivary Neutrophil-to-Lymphocyte Ratio as a Prognostic Predictor of Oral Premalignant and Malignant Disorders: A Prospective Study. *Cureus*. 2024 Mar 16; 16(3): e56273. doi: 10.7759/cureus.56273. PMID: 38623101; PMCID: PMC11017949.

26. Cheng G, Liu F, Niu X, Fang Q. Role of the pretreatment neutrophil-to-lymphocyte ratio in the survival of primary parotid cancer patients. *Cancer Manag Res*. 2019 Mar 21;11:2281-2286. doi: 10.2147/CMAR.S195413. PMID: 30962717; PMCID: PMC6432895.

27. Szilasi Z, Jóna V, Zrubka Z, Mezei T, Vass T, Merkel K, Helfferich F, Baranyai Z. Neutrophil-To-Lymphocyte and Platelet-To-Lymphocyte Ratios as Prognostic Markers of Survival in Patients with Head and Neck Tumours-Results of a Retrospective Multicentric Study. *Int J Environ Res Public Health*. 2020 Mar 7;17(5):1742. doi: 10.3390/ijerph17051742. PMID: 32155982; PMCID: PMC7084240.

28. Lee RH, Truong A, Wu X, et al. The neutrophil-to-lymphocyte ratio in salivary gland cancers treated with pembrolizumab. *Head & Neck*. 2024; 46(1): 129-137. doi:10.1002/hed.27565

29. Bora A. Is the neutrophil-to-lymphocyte ratio a marker for differentiating between benign and malignant submandibular gland masses? *Rev Assoc Med Bras (1992)*. 2023 Oct 27;69(11):e20230738. doi:10.1590/1806-9282.20230738. PMID: 37909621; PMCID: PMC10610767.